Scientists have redesigned a key piece of MRI hardware using metamaterials, allowing existing scanners to produce clearer ...
NEW YORK & LONDON--(BUSINESS WIRE)--The Visualize Group (“Visualize”), a private investment firm focused on investing in mission-critical, services-based companies, today announced that it has agreed ...
With this approval, AMBELVIST becomes the lowest-dose mGBCA in the U.S. AMBELVIST has a recommended dose of 0.01 mmol/kg actual body weight (which delivers 0.04 mmol Gd/kg body weight), representing ...
Bayer today announced that the U.S. Food and Drug Administration (FDA) approved AMBELVIST ® (gadoquatrane), a new, intravenous macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) indicated for ...
Bayer’s AMBELVIST® (gadoquatrane) becomes the lowest-dose macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) approved in the U.S., with a recommended dose of 0.01 mmol/kg actual body weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results